Xeljanz Lawsuit What is, Definition, Meaning
What is the Xeljanz Lawsuit? (2024)
The basis of this lawsuit includes the allegations that the victims of Pfizer’s drug, Xeljanz, which mainly treats autoimmune diseases like ulcerative colitis and arthritis, have caused cardiac problems and blood clot development among them.
Some patients also claim compensation for the health loss caused by Xeljanz-induced cancer. The occurrence of side effects of Xeljanz is common in patients with arthritis and ulcerative colitis.
The lawsuits against Xeljanz are increasing rapidly in the USA. Therefore, there is a prominent involvement of the FDA in this lawsuit to deeply study the intricate aspects of the Xeljanz-blood clot lawsuit successfully.
Frequently Asked Questions
Xeljanz and Rinvoq are both Janus Kinase inhibitors that are useful for treating major autoimmune problems. The Rinvoq drug is a common alternative to the Xeljanz, which is healthier for usage. It does not create a negative impact on the health of the users like Xeljanz and performs its role safely and securely.
The black box warning for Janus kinase (JAK) inhibitors like Xeljanz means that these drugs can be harmful to the health of the users. Severe health complications like infections, cancer, and blood clots result in the over usage of Xeljanz. With the help of black box warnings for JAK inhibitors, users can be more careful about taking this medication in the future.
Pfizer is the producer of Xlejanz, which is responsible for the quality control, production, and marketing of Xeljanz. Due to this reason, the victims of Xeljanz consider Pfizer responsible for the health losses they have been suffering from.